Sign In
Buy SCYX
$4.67
-0.430 (-8.43%)
At Close: Jun 03, 2026
SCYNEXIS (SCYX) to Release Earnings on Wednesday
02:45am, Tuesday, 04'th Nov 2025
SCYNEXIS (NASDAQ: SCYX - Get Free Report) is anticipated to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.21)
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
08:00am, Wednesday, 15'th Oct 2025
JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
JERSEY CITY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:30pm, Wednesday, 13'th Aug 2025
JERSEY CITY, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC bought a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities &
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
08:30am, Wednesday, 28'th May 2025
JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
05:08pm, Wednesday, 12'th Mar 2025
JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04:30pm, Wednesday, 06'th Nov 2024
JERSEY CITY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
08:00am, Thursday, 10'th Oct 2024
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
08:00am, Thursday, 03'rd Oct 2024
JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
08:00am, Tuesday, 27'th Aug 2024
JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
04:30pm, Thursday, 08'th Aug 2024
JERSEY CITY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
3 Stocks Under $10 With the Potential for Massive Gains
06:24am, Monday, 22'nd Jul 2024
Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to b
3 Dirt-Cheap Drug Developers With Blockbuster Potential
07:00am, Thursday, 11'th Jul 2024
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech
